Diaceutics Reports Advancements in Rare-Disease Offerings

August 28, 2024 01:08 AM AEST | By Team Kalkine Media

Google News:

Diaceutics Reports Advancements in Rare-Disease Offerings — Image source: shutterstock

Recent News

Carney launches ‘One Canadian Economy’ Act to unify trade, approvals

Trump signs orders to enhance drone defenses, support supersonic trave...

US job growth in May tops forecasts, but Macquarie warns cracks are em...

U.S. Treasury, Commerce secretaries and Trade Representative to meet C...

Diaceutics (LSE:DXRX) announced a major enhancement to its rare-disease offerings on Tuesday, marked by the acquisition of a new contract designed to support the commercialization of a therapy for rare diseases.

The AIM-listed company revealed that the expansion is set to transform the early identification of patients, a crucial aspect for pharmaceutical companies developing treatments for rare conditions.

A key component of this enhancement is the broadened lab network, which now features several new genomic lab data partners specializing in rare diseases. Notably, the addition of the largest genetic testing lab in the US is expected to provide essential data for improving early patient diagnosis.

The expanded network is anticipated to be instrumental in identifying rare disease patients at earlier stages, thereby improving clinical outcomes and enhancing the likelihood of successful treatments.

Diaceutics also highlighted advancements in its lab labeling capabilities, achieved through the implementation of natural language processing (NLP) technology. This upgraded NLP process enables more accurate and standardized data processing, addressing a longstanding challenge by differentiating between pathogenic variants and variants of unknown significance (VUS).

The company noted that these technological improvements are projected to significantly enhance the value of the data utilized by pharmaceutical companies in diagnosing and treating rare diseases.

Additionally, Diaceutics has strengthened its team by incorporating industry experts with extensive experience in rare diseases. This expanded expertise is intended to assist biopharma clients in maximizing the benefits of Diaceutics' advanced data capabilities and meeting the complex needs of this specialized market.

The recent strategic enhancements have already led to a successful contract win, providing a multi-product solution to support the commercialization of a therapy for a rare autosomal-recessive disease.

Chief Data Officer Jordan Clark commented, “These enhancements to our rare-disease data offering represent significant progress in our mission to support the earlier identification and treatment of patients with rare diseases. By integrating new data, advanced labeling, and a specialized team, we are well-positioned to address the critical needs of this underserved market and aid patients in need.”

At 1110 BST, shares in Diaceutics increased by 2.69% to 133.5p

Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (Kalkine Media, we or us), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.